Search

Your search keyword '"Held S"' showing total 594 results
Start Over Author "Held S"
594 results on '"Held S"'

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI

Author

Alig, A.H.S., Modest, D.P., Stintzing, S., Heinrich, K., Geissler, M., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Held, S., Moosmann, N., Stahler, A., Tannapfel, A., Giessen-Jung, C., Jung, A., Weiss, L., and Heinemann, V.

Published
2024
Full Text
View/download PDF

2. Dermatology-related quality-of-life outcomes in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: a prespecified secondary analysis of the phase II randomized PanaMa (AIO KRK 0212) trial

Author

Ballhausen, A., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A.O., von Weikersthal, L.F., Sommerhäuser, G., Jelas, I., Alig, A.H.S., Kurreck, A., Stahler, A., Goekkurt, E., Held, S., Kasper, S., Heinrich, K., Heinemann, V., Stintzing, S., Trarbach, T., and Modest, D.P.

Published
2024
Full Text
View/download PDF

3. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)

Author

Boukovala, M., Modest, D.P., Ricard, I., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Peveling Genannt Reddemann, C., Graeven, U., Schuch, G., Schwaner, I., Heinrich, K., Neumann, J., Jung, A., Held, S., Stintzing, S., Heinemann, V., and Michl, M.

Published
2024
Full Text
View/download PDF

4. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

Author

Heinrich, K., Karthaus, M., Fruehauf, S., Graeven, U., Mueller, L., König, A.O., von Weikersthal, L. Fischer, Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Alig, A.H.S., Kurreck, A., Stahler, A., Held, S., Sommerhäuser, G., Heinemann, V., Stintzing, S., Trarbach, T., and Modest, D.P.

Published
2023
Full Text
View/download PDF

6. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Author

Hartlapp, I., Valta-Seufzer, D., Siveke, J.T., Algül, H., Goekkurt, E., Siegler, G., Martens, U.M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T.J., Held, S., Keller, R., Anger, F., Germer, C.T., Stang, A., Kimmel, B., Heinemann, V., and Kunzmann, V.

Published
2022
Full Text
View/download PDF

7. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Author

Stintzing, S., Wirapati, P., Lenz, H.-J., Neureiter, D., Fischer von Weikersthal, L., Decker, T., Kiani, A., Kaiser, F., Al-Batran, S., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Moehler, M., Scheithauer, W., Held, S., Modest, D.P., Jung, A., Kirchner, T., Aderka, D., Tejpar, S., and Heinemann, V.

Published
2019
Full Text
View/download PDF

8. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Author

Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C., and Modest, D. P.

Published
2020
Full Text
View/download PDF

9. Corrigendum to “Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]

Author

Hartlapp, I., Valta-Seufzer, D., Siveke, J.T., Algül, H., Goekkurt, E., Siegler, G., Martens, U.M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T.J., Held, S., Keller, R., Anger, F., Germer, C.T., Stang, A., Kimmel, B., Heinemann, V., and Kunzmann, V.

Published
2024
Full Text
View/download PDF

10. Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)”: [ESMO Open 7 (2024) 100552]

Author

Hartlapp, I., Valta-Seufzer, D., Siveke, J.T., Algül, H., Goekkurt, E., Siegler, G., Martens, U.M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T.J., Held, S., Keller, R., Anger, F., Germer, C.T., Stang, A., Kimmel, B., Heinemann, V., and Kunzmann, V.

Published
2024
Full Text
View/download PDF

11. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II

Author

Dietz, A., Wichmann, G., Kuhnt, T., Pfreundner, L., Hagen, R., Scheich, M., Kölbl, O., Hautmann, M.G., Strutz, J., Schreiber, F., Bockmühl, U., Schilling, V., Feyer, P., de Wit, M., Maschmeyer, G., Jungehülsing, M., Schroeder, U., Wollenberg, B., Sittel, C., Münter, M., Lenarz, T., Klussmann, J.P., Guntinas-Lichius, O., Rudack, C., Eich, H.T., Foerg, T., Preyer, S., Westhofen, M., Welkoborsky, H.J., Esser, D., Thurnher, D., Remmert, S., Sudhoff, H., Görner, M., Bünzel, J., Budach, V., Held, S., Knödler, M., Lordick, F., Wiegand, S., Vogel, K., Boehm, A., Flentje, M., and Keilholz, U.

Published
2018
Full Text
View/download PDF

13. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

Author

Haas, M., Siveke, J.T., Schenk, M., Lerch, M.M., Caca, K., Freiberg-Richter, J., Fischer von Weikersthal, L., Kullmann, F., Reinacher-Schick, A., Fuchs, M., Kanzler, S., Kunzmann, V., Ettrich, T.J., Kruger, S., Westphalen, C.B., Held, S., Heinemann, V., and Boeck, S.

Published
2018
Full Text
View/download PDF

16. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Author

Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Held, S., Moehler, M., Jagenburg, A., Kirchner, T., Jung, A., and Heinemann, V.

Published
2017
Full Text
View/download PDF

18. Increased oxygen uptake in well-trained runners via uphill running: A randomized crossover testing

Author

Held, S., Rappelt, L., Wiedemann, T., Deutsch, J., Wicker, Pamela, Donath, L., and Giesen, Ronja

Subjects
incline, injury, intervals, running, performance
Abstract

The time spent above 90% of maximal oxygen uptake (V_O2max) during highintensity interval training (HIIT) sessions is intended to be maximized to improve V_O2max. Since uphill running serves as a promising means to increase metabolic cost, we compared even and moderately inclined running in terms of time ≥90% V_O2max and its corresponding physiological surrogates. Seventeen well-trained runners (8 females & 9 males; 25.8 ± 6.8yrs; 1.75 ± 0.08m; 63.2 ± 8.4kg; V_O2max: 63.3 ± 4.2 ml/min/kg) randomly completed both a horizontal (1% incline) and uphill (8% incline) HIIT protocol (4-times 5min, with 90s rest). Mean oxygen uptake (V_O2mean), peak oxygen uptake (V_O2peak), lactate, heart rate (HR), and perceived exertion (RPE) were measured. Uphill HIIT revealed higher (p ≤ 0.012; partial etasquared (pes) ≥ 0.351) V_O2mean (uphill: 3.3 ± 0.6 vs. horizontal: 3.2 ± 0.5 L/min; standardized mean difference (SMD) = 0.15), V_O2peak (uphill: 4.0 ± 0.7 vs. horizontal: 3.8 ± 0.7 L/min; SMD = 0.19), and accumulated time ≥90% V_O2max (uphill: 9.1 ± 4.6 vs. horizontal: 6.4 ± 4.0 min; SMD = 0.62) compared to even HIIT. Lactate, HR, and RPE responses did not show mode*time rANOVA interaction effects (p ≥ 0.097; pes ≤0.14). Compared to horizontal HIIT, moderate uphill HIIT revealed higher fractions of V_O2max at comparable perceived efforts, heartrate and lactate response. Therefore, moderate uphill HiiT notably increased time spent above 90% V_O2max.

Published
2023

22. 424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)

Author

Stintzing, S., primary, Dechow, T.N., additional, Vehling-Kaiser, U., additional, Lorenzen, S., additional, Hannig, C-V., additional, Schwaner, I., additional, Fischer von Weikersthal, L., additional, Puchtler, G., additional, Binder, M., additional, Held, S., additional, Heinrich, K., additional, and Heinemann, V., additional

Published
2022
Full Text
View/download PDF

23. 396P Impact of depth of response of induction therapy on consecutive maintenance therapy in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

Author

Sommerhäuser, G.M., primary, Kurreck, A., additional, Fehrenbach, U., additional, Beck, A., additional, Karthaus, M., additional, Fruehauf, S., additional, Graeven, U., additional, Müller, L., additional, Koenig, A.O., additional, Fischer von Weikersthal, L., additional, Goekkurt, E., additional, Haas, S., additional, Stahler, A., additional, Heinemann, V., additional, Held, S., additional, Alig, A.H.S., additional, Kasper, S., additional, Stintzing, S., additional, Trarbach, T., additional, and Modest, D.P., additional

Published
2022
Full Text
View/download PDF

25. Usher syndrome type IV: clinically and molecularly confirmed by novel ARSG variants

Author

Velde, H.M., Reurink, J.A., Held, S., Li, C.H.Z., Yzer, S., Oostrik, J., Weeda, J.A., Haer-Wigman, L., Yntema, H.G., Roosing, S., Pauleikhoff, L., Lange, C de, Whelan, L., Dockery, A., Zhu, Z., Keegan, D.J., Farrar, G.J., Kremer, H., Lanting, C.P., Damme, M., Pennings, R.J.E., Velde, H.M., Reurink, J.A., Held, S., Li, C.H.Z., Yzer, S., Oostrik, J., Weeda, J.A., Haer-Wigman, L., Yntema, H.G., Roosing, S., Pauleikhoff, L., Lange, C de, Whelan, L., Dockery, A., Zhu, Z., Keegan, D.J., Farrar, G.J., Kremer, H., Lanting, C.P., Damme, M., and Pennings, R.J.E.

Abstract

Item does not contain fulltext, Usher syndrome (USH) is an autosomal recessively inherited disease characterized by sensorineural hearing loss (SNHL) and retinitis pigmentosa (RP) with or without vestibular dysfunction. It is highly heterogeneous both clinically and genetically. Recently, variants in the arylsulfatase G (ARSG) gene have been reported to underlie USH type IV. This distinct type of USH is characterized by late-onset RP with predominantly pericentral and macular changes, and late onset SNHL without vestibular dysfunction. In this study, we describe the USH type IV phenotype in three unrelated subjects. We identified three novel pathogenic variants, two novel likely pathogenic variants, and one previously described pathogenic variant in ARSG. Functional experiments indicated a loss of sulfatase activity of the mutant proteins. Our findings confirm that ARSG variants cause the newly defined USH type IV and support the proposed extension of the phenotypic USH classification.

Published
2022

26. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Author

Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V, Kunzmann, V, Hartlapp, I, Valta-Seufzer, D., Siveke, J. T., Algul, H., Goekkurt, E., Siegler, G., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T. J., Held, S., Keller, R., Anger, F., Germer, C. T., Stang, A., Kimmel, B., Heinemann, V, and Kunzmann, V

Abstract

Background: The prognostic and predictive value of carbohydrate antigen 19-9 (CA 19-9) in locally advanced pancreatic cancer (LAPC) has not yet been defined from prospective randomized controlled trials (RCTs). Patients and methods: A total of 165 LAPC patients were treated within the NEOLAP RCT for 16 weeks with multiagent induction chemotherapy [ICT; either nab-paclitaxel/gemcitabine alone or nab-paclitaxel/gemcitabine followed by FOLFIRINOX (combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin)] followed by surgical exploration of all patients without evidence of disease progression. CA 19-9 was determined at baseline and after ICT and correlated with overall survival (OS) and secondary R0 resection rate. Results: From the NEOLAP study population (N = 165) 133 patients (81%) were evaluable for CA 19-9 at baseline and 81/88 patients (92%) for post-ICT CA 19-9 response. Median OS (mOS) in the CA 19-9 cohort (n = 133) was 16.2 months [95% confidence interval (CI) 13.0-19.4] and R0 resection (n = 31; 23%) was associated with a significant survival benefit [40.8 months (95% CI 21.7-59.8)], while R1 resected patients (n = 14; 11%) had no survival benefit [14.0 (95% CI 11.7-16.3) months, hazard ratio (HR) 0.27; P = 0.001]. After ICT most patients showed a CA 19-9 response (median change from baseline: -82%; relative decrease >= 55%: 83%; absolute decrease to <= 50 U/ml: 43%). Robust CA 19-9 response (decrease to <= 50U/ml) was significantly associated with mOS [27.8 (95% CI 18.4-37.2) versus 16.5 (95% CI 11.7-21.2) months, HR 0.49; P = 0.013], whereas CA 19-9 baseline levels were not prognostic for OS. Multivariate analysis demonstrated that a robust CA 19-9 response was an independent predictive factor for R0 resection. Using a CA 19-9 decrease to <= 61 U/ml as optimal cut-off (by receiver operating characteristic analysis) yielded 72% sensitivity and 62% specificity for successful R0 resection, whereas CA 19-9 nonresponders (<20% decrease or increase)

Published
2022

28. Analyse zweier prospektiver klinischer Studien der Arbeitsgemeinschaft Internistische Onkologie mit der 'Burden of Therapy' (BOTh®TM) Methode : einem neuen Instrument zur Evaluation unerwünschter Ereignisse beim metastasierten Pankreaskarzinom

Author

Dorman, K., Heinemann, V., Snijder, R. J., Waldschmidt, D. T., Freiberg-Richter, J., Siveke, Jens T., Fischer von Weikersthal, L., Reinacher-Schick, A., Schenk, M., Mayerle, J., Caca, K., Stahl, Michael, Kullmann, F., Zhang, D., Held, S., Abdul-Ahad, A., von Bergwelt-Baildon, M., Boeck, S., and Haas, M.

Subjects
Medizin
Abstract

Poster-Abstract

Published
2022

30. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

Author

von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., and Modest, D. P.

Published
2014
Full Text
View/download PDF

31. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

Author

Stahler, A., Heinemann, V., Giessen-Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., von Weikersthal, Fischer L., Vehling-Kaiser, U., Stauch, M., Quietzsch, D., Held, S., von Einem, J. C., Holch, J., Neumann, J., Kirchner, T., Jung, A., and Modest, D. P.

Published
2016
Full Text
View/download PDF

34. 1477P Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Author

Hartlapp, I., primary, Valta-Seufzer, D., additional, Siveke, J., additional, Algül, H., additional, Goekkurt, E., additional, Siegler, G.M., additional, Martens, U.M., additional, Waldschmidt, D., additional, Pelzer, U., additional, Fuchs, M., additional, Kullmann, F., additional, Boeck, S., additional, Ettrich, T.J., additional, Held, S., additional, Keller, R., additional, Anger, F., additional, Germer, C-T., additional, Stang, H.A., additional, Heinemann, V., additional, and Kunzmann, V., additional

Published
2021
Full Text
View/download PDF

35. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology

Author

Gyberg, Viveca, De Bacquer, Dirk, Kotseva, Kornelia, De Backer, Guy, Schnell, Oliver, Sundvall, Jouko, Tuomilehto, Jaakko, Wood, David, Rydén, Lars, Kotseva, K., De Backer, G., Amouyel, P., Bruthans, J., Castro Conde, A., Cifkova, R., De Bacquer, D., De Sutter, J., Deckers, J.W., Dilic, M., Dolzhenko, M., Erglis, A., Ferreira, T., Fraz, Z., Gaita, D., Gielen, S., Gotcheva, N., Goudevenos, I., Gyberg, V., Heuschmann, P., Laucevicius, A., Lehto, S., Lovic, D., Manini, M., Maggioni, A.P., Miličić, D., Moore, D., Nicolaides, E., Pajak, A., Pogosova, N., Reiner, Ž., Rydén, L., Schnell, O., Stagmo, M., Störk, S., Sundvall, J., Tokgözoğlu, L., Tuomilehto, J., Vulic, D., Wood, D., Wood, D.A., Kotseva, K., Jennings, C., Adamska, A., Rydén, L., Gyberg, V., Tuomilehto, J., Schnell, O., Manini, M., Ferreira, T., Taylor, C., Konte, M., Glemot, M., De Bacquer, D., De Backer, G., Sundvall, J., Lund, L., Leiviskä, J., De Bacquer, D., De Backer, G., De Pauw, M., Ghysbrecht, C., Vervaet, P., Maria Middelares, A.Z., De Sutter, J., Pardaens, S., Willems, A.M., Sint Lucas, A.Z., Cambier, P., Claeys, R., Deweerdt, N., Nimmegeers, J., Vandekerckhove, H., Verloove, H., Versee, L., Vulic, D., Djekic, D., Malesevic, G., Pejicic, S., Srdic, S., Dilic, M., Begic, A., Hodzic, E., Kulic, M., Sabanovic-Bajramovic, N., Tahirovic, E., Iveljic, I., Kovcic, J., Kusljugic, Z., Nurkic, M., Gotcheva, N., Baycheva, V., Georgiev, B., Vladimirov, G., Gotchev, D., Ivanov, S., Miličić, D., Samardžić, J., Perić, B., Sičaja, M., Nicolaides, E., Eftychiou, C., Eteocleous, N., Georgiou, P., Hadjilouca, C., Moutiris, J.A., Nicolaou, R., Papadopoulos, K., Patsalou, M., Bruthans, J., Cífková, R., Krajcoviechova, A., Wohlfahrt, P., Filipovský, J., Krizek, M., Kviderova, Z., Mayer, O., Vágovičová, P., Vanek, J., Seidlerova, J., Timoracká, K., Adamkova, V., Belohoubek, J., Galovcova, M., Zelenkova, V., Lehto, S., Kiljander, E., Kiljander, P., Kylmaoja, P., Lehto, H.R., Olkkonen, S., Pennanen, J., Herranen, M., Amouyel, P., Astolfi, A.L., Balik, S., Beauchant, S., Dallongeville, J., Devoghelaere, C., Fievet, N., Garboni, P., Lemaire, B., Marecaux, N., Montaye, M., Karmann, W., Held, S., Heuschmann, P., Eichstädt, K., Deckert, L., Fischer, D., Gerhardt, A., Kircher, J., Memmel, Y., Nolte, K., Schich, M., Wahl, V., Wagner, M., Störk, S., Ertl, G., Güntner, S., Leyh, R., Goudevenos, I., Kalantzi, K., Athanassias, D., Goumas, G., Krimbas, P., Richter, D., Sakellariou, D., Agrios, J., Matthaios, I., Papadopoulou, E., Toumanidis, S., Tsouna-Hatjis, E., Boufidou, A., Makedou, K., Lilis, L., Moore, D., Broderick, G., Fallon, N., Storey, S., Baronenko, I., Dormidontova, G., Dulkevica, A., Dzerve, V., Erglis, A., Andrejeva, T., Bricina, N., Jakovleva, J., Jaunromane, A., Keive, E., Klovane, M., Lurina, D., Makarova, L., Matisone, D., Mintale, I., Pahomova-Strautina, E., Putane, L., Stabulniece, M., Vasiljevs, D., Vevere, G., Vilks, J., Laucevicius, A., Alitoit, I., Badariene, J., Grabliauskaite, I., Jursyte, I., Paleviciute, E., Petrulioniene, Z., Serpytis, P., Serpytis, R., Solovjova, S., Smagriunaite, V., Babarskiene, R., Ceponiene, I., Gustiene, O., Karaliute, R., Rumbinaite, E., Slapikas, R., Smalinskas, V., Verseckaite, R., Pająk, A., Brzezicka, E., Łysek, R., Misiowiec, W., Wolfshaut-Wolak, R., Nessler, J., Podolec, P., Mirek-Bryniarska, E., Grodecki, J., Czarnecka, D., Łukaszewska, A., Jankowski, P., Bogacki, P., Gaita, D., Avram, C., Barzuca, E., Gaita, L., Jurca-Simina, F., Iancu, O.C., Lazar, A., Iurciuc, M., Iurciuc, S., Mal, M., Mancas, S., Mihaescu, A., Mociar, D., Mosteoru, S., Pescariu, S., Petrescu, L., Sasec, C., Schiller, A., Amarie, L., Andronic, A., Calin, S., Ciobanu, A., Cotoban, A., Guberna, S., Lungeanu, L., Mihalcea, D., Niculescu, N., Rimbas, R., Udroiu, C., Vinereanu, D., Pogosova, N., Ausheva, A., Boytsov, S., Kursakov, A., Oganov, R., Pozdnyakov, Y., Skazin, N., Lovic, D., Lovic, B., Nedeljkovic, M., Ostojic, M., Djordjevic, D., Kostic, S., Tasic, I., Zdravkovic, M., Anđić, M., Filipović, T., Ilić-Stojanović, O., Ješić-Jukić, M., Jevsnik, N., Lazović, M., Radović, A., Radović, D., Rosić, D., Spiroski, D., Stevović, S., Vidaković, T., Vuković-Dejanović, V., Fras, Z., Jug, B., Juhant, A., Poljancic, A., Poljancic, L., Castro Conde, A., Dalmau Gonzalez-Gallarza, R., Iniesta Manjavacas, A.M., Stagmo, M., Jernhed, H., Stensgaard, E., Gyberg, V., Boström, V., Edman Jönsson, C., Hage, C., Deckers, J.W., Khatibi, S., Yongzhao, F., Veerhoek, M., Smits, P.C., Minneboo, M., Peters, R.J.G., Scholte op Reimer, W., Snaterse-Zuidam, M., Tokgözoğlu, L., Asil, S., Kaya, B., Koçyiğit, D., Kozluca, V., Tulunay Kaya, C., Akyldz, İ., Ergene, O., Varş, E., Akdeniz, B., Göldeli, Ö., Kozan, Ö., Özpelit, E., Altay, S., Çam, N., Eren, M., Kaykçoğlu, M., Kültürsay, H., Aytekin, V., Burak Çatakoğlu, A., Abac, A., Candemir, M., Ünlü, S., Oğuz, A., Barçn, C., Yaşar, S., Yokuşoğlu, M., Aydoğdu, S., Temizhan, A., Ünal, S., Altuğ Çakmak, H., Çimci, M., Öngen, Z., Ateş, G., Koylan, N., Emet, S., Umman, B., Bostan, C., Sansoy, V., Kemal Erol, M., Kemal Kalkan, A., Kaymaz, C., Poçi, N., Dolzhenko, M., Getman, T., Konoplyanik, L., Klimenko, L., Lobach, L., Luchinskaya, Y., Lurie, L., Lutay, M., Mitchenko, E., Nemchena, O., Nosenko, N., Perepelchenko, N., Potashev, S., Radchenko, A., Romanov, V., Shumakov, V., Simagina, T., Sirenko, Y., Sychov, O., Mohnacheva, N., Verezhnikova, A., Zharinov, O., Lishnevskaya, V., Mikropulo, I., Prihodko, V., Shapovalenko, I., Wood, D., Adamska, A., Evans, J., Ioannides, K., Jennings, C., Kasonta, A., Kotseva, K., Onyango, H., Rapacz, A., Wrotniak, B., Dubrey, S., Barbir, M., Connolly, S., Dancy, M., Collins, P., and Kaprielian, R.

Published
2015
Full Text
View/download PDF

37. PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)

Author

Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Hielscher, J., Lerch, M., Scheithauer, W., Jagenburg, A., Held, S., Modest, D., Jung, A., Kirchner, T., and Heinemann, V.

Published
2016
Full Text
View/download PDF

39. The Acoculco High Temperature Area in Mexico: Resistivity Survey (TEM and MT); Data Acquisition, Processing and Inversion - Geological Significance

Author

Hersir G.P.[1], Arango Galván C.[2], Benediktsdóttir A.[1], Held S.[3], Romo Jones J.M.[4], Salas J.L.[2], Aviles T.[4], Ruiz Aquilar D.[5], Vilhjálmsson A.M.[1], Manzella A.[6], and Santilano A.[6]

Subjects
GEMex, Acoculco, enhanced geothermal system, resistivity, magnetotellurics, transient electromagnetics, geophysical interpretation
Abstract

GEMex (Cooperation in Geothermal energy research Europe-Mexico for development of Enhanced Geothermal Systems and Superhot Geothermal Systems) is a joint geothermal project of a European and Mexican consortium which began in late 2016 with the purpose to develop geothermal energy in the easternmost region of the Trans-Mexican Volcanic Belt. Two sites that belong to the Comisión Federal de Electricidad (CFE) have been investigated. One of them, the Los Humeros high-temperature area is a superhot geothermal system. The other one, Acoculco high-temperature geothermal area has been proposed to develop an Enhanced Geothermal System (EGS). To characterize an EGS development site in Acoculco, extensive geological, geochemical and geophysical studies were carried out. Already existing regional gravity and magnetic maps were analysed, and gravity was measured on a dense grid. A total of 18 micro-seismic stations were set up which collected data for about a year. Finally, 68 colocated MT and TEM soundings were measured in 2017-2019 through a joint effort by the European and Mexican partners. Their location was based on the interpretation of already existing resistivity measurements as well as a recent geological model of the area. The TEM was measured using TerraTEM equipment and the MT data were collected using instruments from the Metronix manufacturer. The Bounded Influence Remote Reference Processing method (BIRRP) was used for processing the MT time-series. Each TEM/MT pair was jointly inverted in 1D, using the TEM data to static shift correct the MT data. The authors wish to thank the Comisión Federal de Electricidad (CFE) for their assistance and support. This paper presents results of the GEMex Project, funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 727550, and by the Mexican Energy Sustainability Fund CONACYT-SENER, Project 2015-04-268074. More information can be found on the GEMex Website: http://www.gemex-h2020.eu.

Published
2021

40. The Los Humeros Superhot Geothermal Resource in Mexico: Resistivity Survey (TEM and MT); Data Acquisition, Processing and Inversion - Geological Significance

Author

Benediktsdóttir A.[1], Arango Galván C.[2], Hersir G.P.[1], Held S.[3], Romo Jones J.M.[4], Salas J.L.[2], Aviles T.[4], Ruiz Aquilar D.[5], Vilhjálmsson A.M.[1], Manzella A.[6], and Santilano A.[6]

Subjects
Los Humeros, superhot geothermal resource, resistivity, magnetotelluris, transient electromagnetics, geophysical interpretation
Abstract

A joint geothermal project of a European and Mexican consortium began in late 2016 with the purpose to develop geothermal energy in the easternmost region of the Trans-Mexican Volcanic Belt. Two sites that belong to the Comisión Federal de Electricidad (CFE) have been investigated. One of the them, Los Humeros, is the subject of our study. In order to further explore the Los Humeros superhot geothermal resource, extensive geological, geochemical and geophysical studies were carried out. Previously existing regional gravity and magnetic maps were studied, and gravity was measured on a dense grid. Some 23 broadband and 22 short period seismic stations were set up which collected data for one year. Finally, 122 co-located MT and TEM soundings were made in 2017 and 2018 through a joint effort by the European and Mexican partners. Their location was based on the interpretation of already existing resistivity data. The TEM and MT data were acquired with a TerraTEM equipment and Metronix equipment, respectively. The bounded influence remote reference processing method was used for processing of the MT timeseries. Each TEM/MT pair was jointly inverted in 1D, where the TEM data were used to static shift correct the MT data. A 3D inversion was performed on the full impedance tensor of the MT data using different initial models. Two codes were applied for comparison, the WSINV3DMT code was run in Europe and ModEM in Mexico. Finally, the resistivity models were compared with and interpreted together with other geoscientific results from the GEMex project, gravity, seismics and the geological mapping. This abstract presents results of the GEMex Project, funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 727550, and by the Mexican Energy Sustainability Fund CONACYT-SENER, Project 2015-04-268074. More information can be found on the GEMex Website: http://www.gemex-h2020.eu

Published
2021

41. The potential of raw material extraction from thermal brines - Successful milestones of the BrineMine project

Author

Goldberg, V., Winter, D., Nietschke, F., Rath, M., Held, S., Spitzmüller, L., Budach, I., Pavez, M., Morata, D., Koschikowski, J., Kohl, T., and Publica

Subjects
Solarthermische Kraftwerke und Industrieprozesse, Thermische Systeme und Gebäudetechnik, Wasseraufbereitung und Stofftrennung
Abstract

The BrineMine Project is a German-Chilean multidisciplinary research project realized by research and industry partners. The focus is on development of strategies for raw material and water extraction from geothermal springs (Brine Mining) in Chile. The topics can be separated into a geological/geochemical part and a mechanical engineering part, which are processed in close cooperation by the project consortium. In the first part, the economic potential of the dissolved raw materials in thermal spring waters in Chile is assessed by analyzing existing geochemical data of different sites. This is complemented by hydrogeochemical and geophysical exploration campaigns. The second part focuses on the development, construction and implementation of a prototype for pre-treatment and concentration of geothermal brines. With the comprehensive expertise of the team, a treatment strategy was developed and tested in a geothermal power plant, enabling controlled silica precipitation in order to overcome this limiting factor for geothermal energy production and associated raw material extraction. In this study, successful milestones of the BrineMine project are presented. The economic potential of elements in Chilean thermal waters is demonstrated. Additionally, the global potential of Brine Mining is outlined. The development of the silica treatment strategy is further described, as well as a possible integration of a prototype into an operating geothermal power plant. Finally, the construction and implementation of a large-scale first-generation prototype are presented with promising field results.

Published
2021

42. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy : Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)

Author

Hartlapp, I., Valta-Seufzer, D., Siveke, Jens, Algül, H., Goekkurt, E., Siegler, G.M., Martens, U.M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., Boeck, S., Ettrich, T.J., Held, S., Keller, R., Anger, F., Germer, C-T., Stang, H.A., Heinemann, V., and Kunzmann, V.

Subjects
Medizin
Published
2021

43. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method

Author

Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S., Heinemann, V, Haas, M., Waldschmidt, D. T., Stahl, M., Reinacher-Schick, A., Freiberg-Richter, J., von Weikersthal, L. Fischer, Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T., Dechow, T., Mahlberg, R., Malfertheiner, P., Illerhaus, G., Kubicka, S., Abdul-Ahad, A., Snijder, R., Kruger, S., Westphalen, C. B., Held, S., Von Bergwelt-Baildon, M., Boeck, S., and Heinemann, V

Abstract

Background: Targeting the epidermal growth factor receptor pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non-small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus afatinib (Gem/afatinib) versus gemcitabine (Gem) alone as first-line treatment for metastatic pancreatic cancer. Patients and methods: Patients were randomised in a 2:1 ratio to either Gem (1000 mg/m(2) weekly for three weeks followed by one week of rest, repeated every four weeks) and afatinib (40 mg orally once daily) or Gem alone. Overall survival (OS) was the primary study endpoint. The novel BOTh(C)(TM) methodology was implemented to derive a quantitative estimate for the 'Burden of Therapy/Toxicity' (BOTh) for each patient on every day during the clinical study. Conclusion: The addition of afatinib to Gem did not improve treatment efficacy and was more toxic. The BOTh(C)(TM) methodology allowed a detailed insight into the course of treatment-related adverse events over the study period. (C) 2021 Elsevier Ltd. All rights reserved.

Published
2021

44. 621P The systemic proteome of consensus molecular subtypes from patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial

Author

Ballhausen, A., Shomroni, O., Stahler, A., Hoppe, B., Karthaus, M., Fruehauf, S., Graeven, U., Sommerhäuser, G.M., Alig, A.H.S., Goekkurt, E., Meyer-Knees, J., Kurreck, A., Held, S., Kasper-Virchow, S., Heinemann, V., Stintzing, S., Trarbach, T., Mülleder, M., Ralser, M., and Modest, D.P.

Published
2023
Full Text
View/download PDF

47. Effects of environmental enrichment and loose housing of lactating sows on piglet performance before and after weaning

Author

Oostindjer, M., Bolhuis, J.E., Mendl, M., Held, S., Gerrits, W., van den Brand, H., and Kemp, B.

Subjects
Swine -- Environmental aspects, Swine -- Physiological aspects, Swine -- Research, Infants -- Weaning, Infants -- Research, Zoology and wildlife conservation
Abstract

We investigated effects of loose housing of the sow during lactation and enrichment of the pen pre- and postweaning on performance of newly weaned piglets. Before weaning, piglets (n = 320) were housed in an enriched (straw, wood shavings, peat, and branches) or barren pen with a confined or loose-housed sow (n = 32). Loose-housed sows and their piglets could eat together from a family feeder, whereas confined sows and piglets had separate feeding troughs. Piglets (n = 256) were mixed postweaning, and 4 piglets from each litter were relocated to a barren pen (n = 32 pens) and 4 other piglets were housed in an enriched pen (n = 32 pens). Growth from d 15 until weaning was greater for piglets from enriched pens (4.38 [+ or ] 0.29 vs. 4.71 [+ or ] 0.21 kg/pig, P < 0.05) and tended to be greater for piglets with a loose-housed sow compared with piglets with a confined sow (4.41 [+ or ] 0.26 vs. 4.67 [+ or ] 0.24 kg/pig, P = 0.10). Preweaning feed intake was not affected by preweaning conditions (P > 0.25). Piglets from enriched preweaning pens ate more in the first 2 d postweaning than piglets from barren pens (first 48 h, barren 0.45 [+ or ] 0.05 kg/pig, enriched 0.53 [+ or ] 0.04 kg/ pig, P < 0.05). Piglets relocated to an enriched pen after weaning showed a greater growth in the 2 wk after weaning (barren 5.5 [+ or ] 0.2 kg/pig, enriched 6.2 [+ or ] 0.2 kg/pig, P < 0.0001), had a profoundly reduced diarrhea prevalence than piglets housed in barren pens after weaning (barren 2.4 [+ or ] 0.4 d, enriched 1.0 [+ or ] 0.3 d, P < 0.0001), and had a greater feed efficiency (barren 0.81 [+ or ] 0.03, enriched 0.85 [+ or ] 0.02, P < 0.05). Enrichment of the preweaning environment likely stimulates development of feeding behaviors and consequently increases feed intake immediately after weaning. Providing piglets with an enriched environment after weaning positively affected postweaning growth, feed efficiency, and incidence of diarrhea, which may be caused by decreased stress or increased gut health. Enrichment of the pre- and postweaning environment seems important in improving performance and health of newly weaned pigs. Key words: environmental enrichment, learning, piglet, sow housing, weaning doi: 10.2527/jas.2010-2940

Published
2010

48. Steerable wavelet frames based on the Riesz transform

Author

Held, S., Storath, M., Massopust, P., and Forster, B.

Subjects
Hilbert space -- Analysis, Image processing -- Analysis, Wavelet transforms -- Usage, Business, Computers, Electronics, Electronics and electrical industries
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results